Relay Therapeutics Inc. (RLAY)
NASDAQ: RLAY · Biological Products, (No Diagnostic Substances) · Cambridge, MA
Our rating: Cautious
Cautious reaffirmed at $19.94, moderate conviction, November 10, 2026.
Breaks if: The Cautious call would be wrong if Relay's November 2026 patent invalidation is reversed on appeal within twelve months, or if a lead pipeline program reports Phase 3 efficacy data sufficient to support an NDA submission in that same window — either outcome would restore the IP or clinical foundation the $4.4 billion market cap is currently pricing without clear support. In price terms, a sustained close above $28 (roughly 40% above today's $19.94) within six months would signal a market re-rating the present evidence does not justify and should trigger a fresh assessment. The call deepens on the downside if annualized free-cash-flow burn deteriorates past −$300 million in either of the next two 10-Q filings with no new financing disclosed alongside it.
Key figures
| Market value | $3.6B |
|---|---|
| Revenue, last 12 months | $10M |
| Net income, last 12 months | −$294M |
| Free cash flow, last 12 months | n/a |
| Price to earnings | n/a |
| Free cash flow yield | n/a |
| Dividend yield | 0.0% |
| Operating margin | −3094.6% |
| Return on equity | −41.2% |
| Beta to the S&P 500 | 1.79 |
| Volatility, annualized | 77.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $0.00 | n/a | $-0.37 | −$64M |
| June 30, 2026 | $350000.00 | −48.3% | $-0.41 | n/a |
| March 31, 2026 | $3M | −60.9% | $-0.41 | n/a |
| December 31, 2025 | $7M | n/a | $-0.31 | −$45M |
| September 30, 2025 | $0.00 | n/a | $-0.43 | −$62M |
| June 30, 2025 | $677000.00 | n/a | $-0.41 | −$55M |
| March 31, 2025 | $8M | −23.3% | $-0.46 | −$74M |
| December 31, 2024 | $0.00 | −100.0% | $-0.42 | −$58M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 2%, Gemini 2%, Mistral 3%
- Free cash flow for the quarter is above zero: Claude 3%, Gemini 2%, Mistral 2%
18 ledger entries and 16 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.